| Poor efficacy group (n = 59) | Effective efficacy group (n = 103) | P value |
---|---|---|---|
Gender, male (%) | 51 (86.4%) | 87 (84.5%) | 0.734 |
Age, years | 46.51 ± 13.7 | 57.7 ± 13.3 | < 0.001 |
Stroke types | |||
 Hemorrhagic, n (%) | 34 (57.6%) | 45 (43.7%) | 0.088 |
 Ischemic, n (%) | 25 (42.4%) | 58 (56.3%) | |
 Hypertension, n (%) | 55 (93.2%) | 84 (81.6%) | 0.041 |
 Diabetes mellitus, n (%) | 17 (28.8%) | 38 (36.9%) | 0.269 |
 Abnormal lipid metabolism, n (%) | 34 (57.6%) | 75 (72.8%) | 0.070 |
 Hyperuricemia, n (%) | 10 (16.9%) | 7 (6.8%) | 0.042 |
HCY, μmol/L | |||
 Before treatment | 26.49 ± 15.75 | 21.88 ± 18.99 | 0.116 |
 After treatment | 21.64 ± 10.81 | 12.42 ± 5.99 | < 0.001 |
MTHFR C677T genotype | |||
 CC, n (%) | 1 (1.7%) | 9 (8.7%) | < 0.001 |
 CT, n (%) | 10 (16.9%) | 45 (43.7%) |  |
 TT, n (%) | 48 (81.4%) | 49 (47.6%) |  |